Menu
Back to User profile » Dr Mohammadreza Akhavanpoor
Papers published by Dr Mohammadreza Akhavanpoor:
Advantageous effects of immunosuppression with tacrolimus in comparison with cyclosporine A regarding renal function in patients after heart transplantation
Helmschrott M, Rivinius R, Ruhparwar A, Schmack B, Erbel C, Gleissner CA, Akhavanpoor M, Frankenstein L, Ehlermann P, Bruckner T, Katus HA, Doesch AO
Drug Design, Development and Therapy 2015, 9:1217-1224
Published Date: 24 February 2015
Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapy
Rivinius R, Helmschrott M, Ruhparwar A, Schmack B, Klein B, Erbel C, Gleissner CA, Akhavanpoor M, Frankenstein L, Darche FF, Thomas D, Ehlermann P, Bruckner T, Katus HA, Doesch AO
Drug Design, Development and Therapy 2015, 9:93-102
Published Date: 17 December 2014
CCL19 and CCL21 modulate the inflammatory milieu in atherosclerotic lesions
Akhavanpoor M, Gleissner CA, Gorbatsch S, Doesch AO, Akhavanpoor H, Wangler S, Jahn F, Lasitschka F, Katus HA, Erbel C
Drug Design, Development and Therapy 2014, 8:2359-2371
Published Date: 27 November 2014
Superior rejection profile during the first 24 months after heart transplantation under tacrolimus as baseline immunosuppressive regimen
Helmschrott M, Beckendorf J, Akyol C, Ruhparwar A, Schmack B, Erbel C, Gleissner CA, Akhavanpoor M, Ehlermann P, Bruckner T, Katus HA, Doesch AO
Drug Design, Development and Therapy 2014, 8:1307-1314
Published Date: 9 September 2014
Inhibition of B7-1 (CD80) by RhuDex® reduces lipopolysaccharide-mediated inflammation in human atherosclerotic lesions
Doesch AO, Zhao L, Gleissner CA, Akhavanpoor M, Rohde D, Okuyucu D, Hakimi M, Dengler TJ, Katus HA, Erbel C
Drug Design, Development and Therapy 2014, 8:447-457
Published Date: 12 May 2014